Advantage Investment Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Advantage Investment Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$8K	Hold	100	–	–	0.01%	679
2019 Q2	$7K	Hold	100	–	–	0.01%	706
2019 Q1	$9K	Hold	100	–	–	0.01%	658
2018 Q4	$7K	Hold	100	–	–	0.01%	713
2018 Q3	$9K	Hold	100	–	–	0.01%	725
2018 Q2	$10K	Hold	100	–	–	0.01%	640
2018 Q1	$12K	Hold	100	–	–	﹤0.01%	635
2017 Q4	$13K	Hold	100	–	–	﹤0.01%	641
2017 Q3	$12K	Hold	100	–	–	﹤0.01%	649
2017 Q2	$8K	Hold	100	–	–	﹤0.01%	740
2017 Q1	$5K	Hold	100	–	–	﹤0.01%	797
2016 Q4	$4K	Hold	100	–	–	﹤0.01%	765
2016 Q3	$7K	Hold	100	–	–	﹤0.01%	676
2016 Q2	$6K	Hold	100	–	–	﹤0.01%	661
2016 Q1	$6K	Hold	100	–	–	﹤0.01%	647
2015 Q4	$9K	Buy	+100	New	+$9.27K	﹤0.01%	577

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Advantage Investment Management's ALNY Position: Q3 2019 in Review

Advantage Investment Management held its Alnylam Pharmaceuticals (ALNY) position steady in Q3 2019 at 100 shares worth $8K. The position accounts for 0.01% of the portfolio, ranked #679.

Advantage Investment Management first reported a position in ALNY in Q4 2015 and has held it in 16 quarters since. The position peaked at $13K in Q4 2017. 281 funds tracked by Wall St. Rank hold ALNY as of Q3 2019.

Advantage Investment Management held 100 shares of Alnylam Pharmaceuticals worth $8K as of Q3 2019.
Advantage Investment Management left its Alnylam Pharmaceuticals share count unchanged in Q3 2019.
Alnylam Pharmaceuticals made up 0.01% of Advantage Investment Management's portfolio in Q3 2019, its #679 holding.
Advantage Investment Management first reported a position in Alnylam Pharmaceuticals in Q4 2015 and has held it in 16 quarters since.
Advantage Investment Management's Alnylam Pharmaceuticals position peaked at $13K in Q4 2017.
281 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2019.

Based on Advantage Investment Management's 13F filing for Q3 2019, filed 8 Oct 2019.